Results of a 12-month, multicenter, randomized trial of everolimus with reduced-exposure cyclosporine versus MMF and standard-exposure cyclosporine in De Novo cardiac transplant recipients

被引：0
|
作者：
Lebmkuhl, H. [1 ]
Livi, U. [2 ]
Arizon, J. [3 ]
Vigano, M. [4 ]
Magelli, C. [5 ]
Boissonnat, P. [6 ]
Gerosa, G. [7 ]
Musumeci, F. [8 ]
Gandjbakhch, I. [9 ]
Vanhaecke, J. [10 ]
Hexham, J. M. [11 ]
Mange, K. C. [11 ]
机构：
[1] Deutsch Herzzentrum Berlin, Berlin, Germany
[2] Osped S Maria Misericordia, Udine, Italy
[3] Hosp Univ Reina Sofia, Cordoba, Spain
[4] Univ Pavia, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy
[5] Az Osp Bologna, Policlin S Orsola, Bologna, Italy
[6] Hop Cardiol Lyon, Lyon, France
[7] Univ Padua, Azienda Osped Padova, Padua, Italy
[8] Osped S Camillo Forlanini Azienda Osped Circonval, Rome, Italy
[9] Hop La Pitie Salpetriere, Serv Chirurg Thorac & Cardiovasc, Paris, France
[10] Univ Hosp Gasthuisberg, Louvain, Belgium
[11] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2008年 / 27卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15
引用
下载
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [31] Wound healing in de novo recipients of cardiac allografts: Everolimus-based immunosuppression versus mmf in combination with cyclosporine
    Arizon, Jose
    Almenar, Luis
    Lemkuhl, Hans
    Livi, Ugolino
    Mususmeci, Francesco
    Maccherini, Massimo
    Mattei, Marie-FranAoise
    Delgado, Juan
    Vermes, Emmanuelle
    Keinlook, Robert
    Mange, Kevin
    Hexham, Mark
    TRANSPLANT INTERNATIONAL, 2007, 20 : 95 - 95
  • [32] Incidence of CMV infection with concentration-controlled everolimus or MMF:: 12-month results from a randomized trial in de novo heart transplant patients
    Pellegrini, Carlo
    Dengler, Thomas
    Branzi, Angelo
    Guillemain, Romain
    Varnous, Shaida
    Gerosa, Gino
    Poncelet, Alain
    Vanhaecke, Johan
    Li, Yulan
    Gezahegen, Yonas
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 571 - 571
  • [33] A PROSPECTIVE CLINICAL TRIAL COMPARING TACROLIMUS-MMF TO CYCLOSPORINE-EVEROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS: 2 YEARS RESULTS
    Favi, Evaldo
    Citterio, Franco
    Spagnoletti, Gionata
    Gargiulo, Antonio
    Romagnoli, Jacopo
    Castagneto, Marco
    TRANSPLANT INTERNATIONAL, 2009, 22 : 241 - 241
  • [34] Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine A microemulsion:: Results of a 12-month, randomized, multicenter study
    Stefoni, S
    Midtved, K
    Cole, E
    Thervet, E
    Cockfield, S
    Buchler, M
    Toselli, L
    Pallardo, LM
    Schena, FP
    Pilmore, H
    Kessler, M
    Chadban, S
    Carreño, CA
    TRANSPLANTATION, 2005, 79 (05) : 577 - 583
  • [35] 12-MONTH ATHENA STUDY: EVEROLIMUS VS. STANDARD REGIMEN IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Witzke, O.
    Opgenoorth, M.
    Sommerer, C.
    Suwelack, B.
    Lehner, F.
    Dragun, D.
    Hauser, I. A.
    Schenker, P.
    Baeumer, D.
    Nashan, B.
    Thaiss, F.
    TRANSPLANT INTERNATIONAL, 2014, 27 : 51 - 51
  • [36] 12-Month Athena Study: Everolimus Vs. Standard Regimen in De Novo Renal Transplant Recipients
    Sommerer, C.
    Suwelack, B.
    Dragun, D.
    Hauser, I.
    Schenker, P.
    Baeumer, D.
    Nashan, B.
    Thaiss, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [37] Efficacy and Safety of Everolimus in De Novo Liver Transplant Recipients-12 Month Results of a Randomized, Multicenter Study.
    Fung, J.
    Nevens, F.
    De Carlis, L.
    Metselaar, H. J.
    Beckebaum, S.
    Saliba, F.
    Jonas, S.
    Sudan, D.
    Fischer, L.
    Duvoux, C.
    Chavin, K. D.
    Jiang, H.
    Hexham, J. M.
    Junge, G.
    De Simone, P.
    LIVER TRANSPLANTATION, 2012, 18 : S109 - S110
  • [38] Efficacy and Safety of Everolimus with Reduced Tacrolimus or Cyclosporine in Pediatric Liver Transplant Recipients: 12-Month Results from H2305 Study
    Weymann, A.
    Ganschow, R.
    Ericzon, B.
    Dhawan, A.
    Sharif, K.
    Martzloff, E. -D.
    Rauer, B.
    Ng, J.
    Lopez, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 234 - 234
  • [39] Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial (vol 23, pg 1084, 2010)
    Dantal, J.
    Berthoux, F.
    Moal, M-C
    Rostaing, L.
    Legendre, C.
    Genin, R.
    Toupance, O.
    Moulin, B.
    Merville, P.
    Rerolle, J-P
    Bayle, F.
    Westeel, P. F.
    Glotz, D.
    Kossari, N.
    Lefrancois, N.
    Charpentier, B.
    Quere, S.
    Di Giambattista, F.
    Cassuto, E.
    TRANSPLANT INTERNATIONAL, 2012, 25 (01) : 138 - 138
  • [40] 12 month report of a 3 arm multicenter comparison of tacrolimus (TAC), MMF or TAC/sirolimus(SRL) and steroids vs cyclosporine microemulsion(CYA), MMF and steroids in de novo cardiac transplant recipients
    Kobashigawa, J. W.
    Miller, L. W.
    Felker, G. M.
    Russel, S. D.
    Ewald, G. A.
    Zucker, M.
    Goldberg, L.
    Eisen, H. J.
    Rayburn, B. K.
    Wagoner, L. E.
    Philbin, E.
    Pereira, N.
    Czerska, B.
    Kormos, R. L.
    Weston, M.
    Conte, J.
    Hosenpud, J.
    Aaronson, K.
    Hill, J.
    Copeland, J. G.
    Czer, L.
    Anderson, A.
    Dec, G. W.
    Torre-Amione, G.
    Yancy, C. W.
    Vega, J. D.
    Jarcho, J. A.
    Mancini, D.
    Bhat, G.
    First, R.
    Fitzsimmons, W.
    Tolzman, D.
    Salm, K.
    Gao, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (02): : S61 - S62
12345